Trial
NCT03698227
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
—
Condition
Advanced Soft Tissue Sarcoma
Intervention
Olaratumab
Why stopped
Lack of efficacy on olaratumab
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-15